Press coverage about Organovo (NASDAQ:ONVO) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Organovo earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.9288765116156 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
Organovo (ONVO) traded down $0.01 on Friday, reaching $1.39. The company’s stock had a trading volume of 676,139 shares, compared to its average volume of 1,630,000. The stock has a market cap of $148.62, a P/E ratio of -3.66 and a beta of 3.08. Organovo has a one year low of $1.32 and a one year high of $3.85.
Organovo (NASDAQ:ONVO) last released its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.38 million. Organovo had a negative return on equity of 65.63% and a negative net margin of 923.89%. The firm’s revenue was down 1.4% compared to the same quarter last year. research analysts expect that Organovo will post -0.36 EPS for the current fiscal year.
Several research analysts have commented on ONVO shares. Zacks Investment Research downgraded Organovo from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th. Citigroup downgraded Organovo to a “market perform” rating in a report on Friday, November 10th. BTIG Research restated a “buy” rating and set a $3.00 price objective on shares of Organovo in a report on Thursday, November 16th. Raymond James Financial downgraded Organovo from an “outperform” rating to a “market perform” rating and set a $5.00 price objective on the stock. in a report on Friday, November 10th. Finally, Jefferies Group restated a “buy” rating and set a $4.00 price objective on shares of Organovo in a report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.60.
COPYRIGHT VIOLATION WARNING: “Organovo (ONVO) Earns Daily News Impact Score of 0.03” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/organovo-onvo-earns-daily-news-impact-score-of-0-03.html.
Organovo Company Profile
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.